Regenxbio Inc (RGNX)
15.77
-0.34
(-2.11%)
USD |
NASDAQ |
Apr 19, 15:49
Regenxbio Debt to Equity Ratio: 0.00 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.00 |
September 30, 2022 | 0.00 |
June 30, 2022 | 0.00 |
March 31, 2022 | 0.00 |
December 31, 2021 | 0.00 |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
Date | Value |
---|---|
March 31, 2019 | 0.00 |
December 31, 2018 | 0.00 |
September 30, 2018 | 0.00 |
June 30, 2018 | 0.00 |
March 31, 2018 | 0.00 |
December 31, 2017 | 0.00 |
September 30, 2017 | 0.00 |
June 30, 2017 | 0.00 |
March 31, 2017 | 0.00 |
December 31, 2016 | 0.00 |
September 30, 2016 | 0.00 |
June 30, 2016 | 0.00 |
March 31, 2016 | 0.00 |
December 31, 2015 | 0.00 |
September 30, 2015 | 0.00 |
June 30, 2015 | 0.00 |
March 31, 2015 | |
December 31, 2014 | -0.4217 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2019
--
Maximum
Jun 2019
--
Average
--
Median
Jun 2019
Debt to Equity Ratio Benchmarks
Sarepta Therapeutics Inc | 1.441 |
Amgen Inc | 10.37 |
Gilead Sciences Inc | 1.094 |
AbbVie Inc | 5.732 |
Bristol-Myers Squibb Co | 1.351 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 573.97M |
Total Liabilities (Quarterly) | 262.23M |
Shareholders Equity (Quarterly) | 311.74M |
Current Ratio | 2.571 |